Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population

被引：44

作者：

Burian, M ^{[1
]}

Grösch, S ^{[1
]}

Tegeder, I ^{[1
]}

Geisslinger, G ^{[1
]}

机构：

[1] Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期

关键词：

CYP2C9; ethnic differences; genetic polymorphism; LightCycler;

D O I：

10.1046/j.1365-2125.2002.01693.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aims The aim was to develop a fast detection method for the polymorphic alleles related to impaired CYP2C9-mediated metabolism. Methods CYP2C9 genotypes were identified in 118 DNA samples using real-time PCR (LightCycler) followed by melting curve analysis. All samples were re-tested by validated PCR-RFLP methodology. Results The concordance between the two methods was 100% for two variant alleles. The frequencies of CYP2C9*1 (wild type), CYP2C9*2 and CYP2C9*3 (with 95% confidence intervals) were 0.81(0.05), 0.14(0.04) and 0.05(0.03), respectively, and are similar to those observed in other Caucasian populations. Conclusions This assay is simple and rapid and may be used for CYP2C9-genotyping in a clinical setting.

引用

页码：518 / 521

页数：4

共 11 条

[1]

Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409

[2] Allelic and functional variability of cytochrome P4502C9 [J].

Bhasker, CR ;

Miners, JO ;

Coulter, S ;

Birkett, DJ .

PHARMACOGENETICS, 1997, 7 (01) :51-58

[3] High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population [J].

García-Martín, E ;

Martínez, C ;

Ladero, JM ;

Gamito, FJG ;

Agúndez, JAG .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :47-49

[4] Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication [J].

Ninomiya, H ;

Mamiya, K ;

Matsuo, S ;

Ieiri, I ;

Higuchi, S ;

Tashiro, N .

THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :230-232

[5] IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].

RETTIE, AE ;

WIENKERS, LC ;

GONZALEZ, FJ ;

TRAGER, WF ;

KORZEKWA, KR .

PHARMACOGENETICS, 1994, 4 (01) :39-42

[6] Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population [J].

Scordo, MG ;

Aklillu, E ;

Yasar, U ;

Dahl, ML ;

Spina, E ;

Ingelman-Sundberg, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :447-450

[7] Genetic association between sensitivity to warfarin and expression of CYP2C9*3 [J].

Steward, DJ ;

Haining, RL ;

Henne, KR ;

Davis, G ;

Rushmore, TH ;

Trager, WF ;

Rettie, AE .

PHARMACOGENETICS, 1997, 7 (05) :361-367

[8] Genetic analysis of the human cytochrome P450 CYP2C9 locus [J].

Stubbins, MJ ;

Harries, LW ;

Smith, G ;

Tarbit, MH ;

Wolf, CR .

PHARMACOGENETICS, 1996, 6 (05) :429-439

[9] The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism [J].

SullivanKlose, TH ;

Ghanayem, BI ;

Bell, DA ;

Zhang, ZY ;

Kaminsky, LS ;

Shenfield, GM ;

Miners, JO ;

Birkett, DJ ;

Goldstein, JA .

PHARMACOGENETICS, 1996, 6 (04) :341-349

[10] The effect of genetic polymorphism of cytochrome P450CYP2C9 on phenytoin dose requirement [J].

van der Weide, J ;

Steijns, LSW ;

van Weelden, MJM ;

de Haan, K .

PHARMACOGENETICS, 2001, 11 (04) :287-291

← 1 2 →